Kalaris Therapeutics announces positive initial data from Phase 1a trial of TH103 in neovascular AMD patients.
TH103 showed significant improvements in visual acuity and retinal anatomy.
The data support TH103's engineered properties and potential treatment durability.
Enhanced Potency
TH103 demonstrated significant visual and anatomic improvements after a single injection.
Extended Treatment Durability
Preliminary data shows the potential for extended durability with TH103, reducing the need for frequent treatments.
Low Plasma Cmax
TH103 showed significantly lower plasma Cmax compared to current anti-VEGF agents, indicating enhanced intraocular retention.
- TH103's engineered properties led to rapid and robust improvements in visual acuity and retinal anatomy.
- The low plasma Cmax of TH103 suggests reduced systemic exposure, aligning with enhanced intraocular retention.
- Initial data indicates the potential for extended treatment durability with TH103, promising long-lasting benefits for patients.
The positive Phase 1a data for TH103 mark a significant milestone for Kalaris Therapeutics, positioning the company for further dose escalation and clinical advancement in the treatment of neovascular AMD.